Future of Celera's KIF6 Test Unclear Amid FDA Rejection, Pending Quest Acquisition

Quest, which plans to acquire Celera by the end of the month, could provide the financial backing to conduct prospective studies for the KIF6 test, or it could decide to scrap the KIF6 program altogether.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.